Participants aged 6 to 21 years received a single intrathecal dose of TSHA-102. 1 The low-dose cohort (n = 4) received 5.7 × ...
The phase 1 ASCEND trial is testing a single intrathecal dose of the investigational AAV9 gene therapy INS1201 in young boys with Duchenne muscular dystrophy. Enrollment is staggered, with a 30-day ...
A quick-read roundup of 10 late-breaking abstracts from the 2026 MDS Congress, from phase 3 Parkinson disease readouts to long-term data in Huntington disease and Tourette syndrome, with the key ...
New analyses found differences in functional outcomes over 2 years among patients aged 8 to 12 years treated with ...
Findings from the phase 3 METEOROID trial showed that satralizumab reduced the risk of relapse in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. An analysis ...
Welcome to NeurologyLive® 's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive 's widespread coverage in ...
An analysis of the phase 3 GEMZ trial presented at CNS 2026 showed that fenfluramine produced comparable seizure reductions and safety outcomes in children and adults with CDKL5 deficiency disorder.
The FDA was busy in September 2026, issuing a number of decisions on potential new therapies, including approvals, clearances ...
Weekly cadence delivers three questions curated by neurologists and clinicians, emphasizing both bedside knowledge and historical context. Topic coverage ranges from neurodegeneration and epilepsy to ...
How clinicians can turn everyday observations into publishable research: spotting the gap, choosing the right paper type, and ...
Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results